Crossref
GLP-1 therapies and cancer risk
Science · 05.11.2026 · 394 (6824) · 612-613
DOI: 10.1126/science.aei1490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 05.11.2026. Verfasst von Blánaid Hicks und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Public Health, Queen's University Belfast, Belfast, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Hypoglycemic Agents, Neoplasms. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Correct interpretation of evidence is essential in a rapidly evolving medical landscape
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Diabetes Mellitus, Type 2Glucagon-Like Peptide 1Hypoglycemic AgentsNeoplasmsGlucagon-Like Peptide-1 Receptor AgonistsObesityHumansGlucagon-Like Peptide-1 Receptor
Substanzen
Glucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists
Autor:innen und Institutionen
- Centre for Public Health, Queen's University Belfast, Belfast, UK.
- Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Zitieren
APA
Hicks, B., & Pottegård, A. (2026). GLP-1 therapies and cancer risk. Science, 394(6824), 612-613. https://doi.org/10.1126/science.aei1490
Vancouver
Hicks B, Pottegård A. GLP-1 therapies and cancer risk. Science. 2026;394(6824):612-613. doi:10.1126/science.aei1490
BibTeX
@article{Hicks2026,
author = {Hicks, Blánaid and Pottegård, Anton},
title = {GLP-1 therapies and cancer risk},
journal = {Science},
year = {2026},
volume = {394},
number = {6824},
pages = {612--613},
doi = {10.1126/science.aei1490}
}
EUVIMED